Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-06-16
|
Benlysta® (belimumab) |
systemic lupus erythematosus (SLE) |
2 |
GSK (UK) |
Autoimmune diseases |
2017-06-16
|
ADCT-301 |
relapsed/refractory Non-Hodgkin or Hodgkin lymphoma |
1 |
ADC Therapeutics (Switzerland) |
Cancer - Oncology |
2017-06-16
|
ADCT-402 |
relapsed or refractory non-Hodgkin's lymphoma |
1 |
ADC Therapeutics (Switzerland) |
Cancer - Oncology |
2017-06-15
|
OSE-127 (Effi-7) |
ulcerative colitis |
preclinical |
OSE Immunotherapeutics (France) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2017-06-15
|
Taltz® (ixekizumab) |
active psoriatic arthritis |
3 |
Eli Lilly (USA - IN) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-06-15
|
GLS-5700 |
Zika virus infection |
1 |
Inovio Pharmaceuticals (USA - PA) |
Infectious diseases |
2017-06-14
|
pracinostat |
myelodysplastic syndrome (MDS) |
2 |
Mei Pharma (USA - CA) Helsinn Group (Switzerland) |
Cancer - Oncology |
2017-06-14
|
SNF472 - hexasodium phytate |
calciphylaxis |
1 |
Sanifit (Spain - Switzerland) |
Rare diseases - Cardiovascular diseases |
2017-06-14
|
[Zr-89]-HuMab-5B1 - MVT-2163 |
locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies |
1 |
MabVax Therapeutics (USA - CA) |
Cancer - Oncology - Diagnostic |
2017-06-14
|
sirukumab |
rheumatoid arthritis |
3 |
Janssen Research & Development, a J&J company (USA - NJ) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-06-14
|
vobarilizumab (ALX-0061) |
moderate to severe rheumatoid arthritis |
2b |
Ablynx (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-06-14
|
vobarilizumab (ALX-0061) |
moderate to severe rheumatoid arthritis |
2b |
Ablynx (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-06-14
|
ARGX-110 |
relapsed/refractory cutaneous T-cell lymphoma (CTCL) |
1b |
Argen-X (Belgium - The Netherlands) |
Cancer - Oncology |
2017-06-13
|
Victoza® (liraglutide) |
type 2 diabetes |
|
Novo Nordisk (Denmark) |
Metabolic diseases |
2017-06-13
|
Diamyd® |
type 1 diabetes |
2 |
Diamyd Medical (Sweden) |
Autoimmune diseases - Metabolic diseases |
2017-06-13
|
Cx601 (adipose derived allogeneic stem cell therapy) |
complex perianal fistulas in patients with Crohn's disease |
3 |
Tigenix (Belgium) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2017-06-12
|
BIVV001 (also known as rFVIIIFc-VWF-XTEN) |
hemophilia A |
1-2 |
Bioverativ (USA - MA) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-06-12
|
dalantercept and axitinib |
advanced renal cell carcinoma |
2 |
Acceleron Pharma (USA - CA) |
Cancer - Oncology |
2017-06-12
|
cabozantinib and atezolizumab |
locally advanced or metastatic urothelial carcinoma (UC), locally advanced or metastatic renal cell carcinoma |
1b |
Exelixis (USA - CA) Roche (Switzerland) |
Cancer - Oncology |
2017-06-12
|
Jardiance® (empagliflozin) |
chronic kidney disease |
|
Boehringer Ingelheim (Germany) Eli Lilly (USA - IN) |
Kidney diseases - Renal diseases |